Vernus BioLab (Taiwan) Co., Ltd.
Update：2026/10/27
Industries
Main Industry
Biotechnology
Main Product/Service
ReAIX process optimization platform integrates artificial intelligence and quantum computing to deliver breakthrough manufacturing optimization solutions for pharmaceutical production. From improving efficiency to significantly reducing costs, ReAIX injects intelligent capabilities into manufacturing workflows to ensure quality and competitiveness. The platform provides manufacturing solutions across all drug modalities, ranging from biologics to small-molecule drugs, enabling scalable and high-efficiency production.
Founded Year
2025
Unified Business No.
60796415
Status
Active
Number of Employees
12
Total Paid-in
Capital
100,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Vernus BioLab (Vernus AI) integrates quantum computing and generative AI to transform pharmaceutical R&D and manufacturing. It aims to break traditional drug development bottlenecks, enhance production capabilities, and build resilient next-generation intelligent pharmaceutical systems.
